ZhaoYin International: The expectation of increased tariffs on innovative drugs in the U.S. will have a limited impact on CXO. Recommend buying 3SBIO and others

Zhao Yin International released a research report, expecting that the U.S. tariffs on innovative drugs will have a limited impact on CXO, recommending to buy companies like 3SBIO. The report pointed out that Sino-U.S. innovative cooperation will continue, domestic demand for innovative drug research and development is recovering, and the MSCI China Healthcare Index outperformed the MSCI China Index. Although there are different voices in the U.S., the Sino-U.S. pharmaceutical industry chain is closely linked, and forced decoupling will harm the interests of both sides. Trump announced that starting from October 1, patented drugs will face a 100% tariff, but multinational pharmaceutical companies that already have plans to establish factories in the U.S. may not be affected